Endoscopic Resection Enters the Conversation for Near-Complete Rectal Cancer Response
Advanced rectal cancer has long forced a difficult tradeoff: pursue radical surgery with clear oncologic margins, or preserve the rectum when treatment response appears deep enough to justify restraint. The study title alone signals that tension. A retrospective multicentre case series in Gut examined endoscopic resection after neoadjuvant therapy in patients with advanced rectal cancer who achieved a near-complete response.
That clinical scenario sits in a narrow space between standard resection and watch-and-wait strategies. A near-complete response suggests major tumor regression, but not the level of certainty that would let every team comfortably defer intervention. Endoscopic removal of residual abnormal tissue offers one possible middle path: tissue acquisition, local control, and pathologic clarification without immediately escalating to major surgery. For selected patients, the appeal is obvious. The rectum is anatomically and functionally unforgiving, and any approach that can reduce the burden of radical surgery carries real bedside weight.
This case series is multicentre and retrospective, which matters because it reflects how such decisions are being made in real practice rather than in a tightly scripted trial environment. It also means the report, at least in the abstracted material available here, should be read as hypothesis-generating rather than practice-changing on its own. No sample size, response definitions, technical outcomes, or recurrence data are available in the excerpt, so the study cannot be described in numerical terms without stepping beyond the evidence provided.
Still, the clinical question is clear. When neoadjuvant treatment has eroded a rectal tumor to a near-complete response, can endoscopic resection serve as a meaningful bridge between organ preservation and oncologic safety? The answer depends on several intertwined issues: whether residual disease is truly limited to the mucosa or submucosa, whether imaging and endoscopy can reliably identify the residual lesion, and whether pathology after resection can confidently exclude deeper residual cancer.
A near-complete response is not the same as a complete response. In rectal cancer, that distinction carries practical consequences. Residual microscopic disease can persist even when the endoscopic appearance is encouraging, and local regrowth after an incomplete assessment can alter the entire treatment course. Endoscopic resection is therefore attractive not because it eliminates uncertainty, but because it attempts to convert uncertainty into a specimen. A resected lesion can answer questions that imaging alone may miss: Is viable tumor still present? Has treatment left only fibrosis? Is the margin free of residual disease? Those answers can influence whether a patient proceeds to immediate surgery, enters close surveillance, or remains within an organ-preservation pathway.
The approach also aligns with a broader shift in rectal cancer management toward response-adapted care. As neoadjuvant strategies have improved tumor regression rates, clinicians have faced more patients whose post-treatment anatomy no longer resembles a straightforward surgical target. In that setting, a less invasive local procedure can be clinically appealing, especially when morbidity from total mesorectal excision, stoma creation, or pelvic nerve injury would be substantial. A one-sentence reality sits underneath all of this: once a rectal tumor has regressed substantially, the next step is often about information as much as treatment.
Retrospective multicentre experience can still be valuable here because it captures the technical and selection issues that determine whether endoscopic resection is feasible. Lesion accessibility, depth of suspected invasion, prior fibrosis from radiation, and operator expertise all affect whether a lesion can be removed safely and completely. Even when the oncologic rationale is strong, the procedure itself may be limited by scar tissue, distorted planes, and an uncertain residual lesion boundary. Those are not abstract concerns; they define whether the technique can be adopted beyond a handful of expert centers.
The title also implies a population with advanced disease rather than early-stage rectal neoplasia. That raises the stakes. In advanced rectal cancer, any local approach must be judged against the possibility of nodal disease or deeper residual tumor outside the reach of an endoscopic specimen. Endoscopic resection can sample the mucosal surface and submucosa, but it cannot replace a full surgical lymphadenectomy. For that reason, patient selection is likely to be the central issue in interpreting this case series. Without rigorous staging and careful post-treatment assessment, organ preservation risks becoming undertreatment.
Even so, the study direction is clinically important. It reflects the increasing pressure to individualize rectal cancer management after neoadjuvant therapy, especially when the response appears almost complete and the morbidity of radical surgery is hard to justify reflexively. The available abstract text does not provide the outcome signals needed to judge safety, completeness, recurrence risk, or how often endoscopic resection changed subsequent management. Those missing details are not trivial; they are the core of the clinical question.
What the title does make plain is the direction of inquiry. Endoscopic resection is being tested as a possible tool in a carefully selected rectal cancer subgroup where response to therapy is deep but not unequivocal. The next question, which this limited abstract does not answer, is whether that strategy can consistently deliver durable local control without compromising oncologic outcomes.